Results of a multicenter phase I/II trial of abiraterone acetate plus BEZ235 in metastatic, castration-resistant prostate cancer (mCRPC)

Authors :: Amy M. Lin
Andrew C. Hsieh
Terence W. Friedlander
Evelyn Hang
Alan H. Bryce
Adam Siegel
Charles J. Ryan
Vivian Weinberg
Source :: Journal of Clinical Oncology. 32:e16042-e16042
Publication Year :: 2014
Publisher :: American Society of Clinical Oncology (ASCO), 2014.
Abstract: e16042 Background: Prostate cancer progression and development of resistance to abiraterone acetate (AA) is associated with loss of PTEN-mediated negative regulation of the PI3K and mammalian targe...

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
business.industry
Abiraterone acetate
Castration resistant
medicine.disease
chemistry.chemical_compound
Prostate cancer
Phase i ii
chemistry
Internal medicine
medicine
business

Full Text Access

Tools